Hypercholesterolemia: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
Line 8: Line 8:
A [[meta-analysis]] estimated that after 5 to 7 years of treatment with [[statin]]s, the  [[relative risk reduction]] of coronary heart disease events is decreased by approximately 30%<ref name="pmid11306236">{{cite journal |author=Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN |title=Screening and treating adults for lipid disorders |journal=American Journal of Preventive Medicine |volume=20 |issue=3 Suppl |pages=77–89 |year=2001 |pmid=11306236 |doi=}}</ref><ref name="webPignone">{{cite web |url=http://www.ahrq.gov/clinic/ajpmsuppl/lipidrr.htm |title=Screening for Lipid Disorders: Recommendations and Rationale |accessdate=2007-10-17 |format= |work=}}</ref>. More recently, a second [[meta-analysis]] reported an almost identical  [[relative risk reduction]] of 29.2% in patients treated for 4.3 years <ref name="pmid17130382">{{cite journal |author=Thavendiranathan P, Bagai A, Brookhart M, Choudhry N |title=Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials |journal=Arch Intern Med |volume=166 |issue=21 |pages=2307-13 |year=2006 |pmid=17130382|doi=10.1001/archinte.166.21.2307}}</ref>. A [[relative risk reduction]] of 19% in coronary mortality was found in a [[meta-analysis]] of patients at all levels of risk.<ref name="pmid16214597">{{cite journal |author=Baigent C, Keech A, Kearney PM, ''et al'' |title=Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins |journal=Lancet |volume=366 |issue=9493 |pages=1267-78 |year=2005 |pmid=16214597 |doi=10.1016/S0140-6736(05)67394-1}}</ref>
A [[meta-analysis]] estimated that after 5 to 7 years of treatment with [[statin]]s, the  [[relative risk reduction]] of coronary heart disease events is decreased by approximately 30%<ref name="pmid11306236">{{cite journal |author=Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN |title=Screening and treating adults for lipid disorders |journal=American Journal of Preventive Medicine |volume=20 |issue=3 Suppl |pages=77–89 |year=2001 |pmid=11306236 |doi=}}</ref><ref name="webPignone">{{cite web |url=http://www.ahrq.gov/clinic/ajpmsuppl/lipidrr.htm |title=Screening for Lipid Disorders: Recommendations and Rationale |accessdate=2007-10-17 |format= |work=}}</ref>. More recently, a second [[meta-analysis]] reported an almost identical  [[relative risk reduction]] of 29.2% in patients treated for 4.3 years <ref name="pmid17130382">{{cite journal |author=Thavendiranathan P, Bagai A, Brookhart M, Choudhry N |title=Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials |journal=Arch Intern Med |volume=166 |issue=21 |pages=2307-13 |year=2006 |pmid=17130382|doi=10.1001/archinte.166.21.2307}}</ref>. A [[relative risk reduction]] of 19% in coronary mortality was found in a [[meta-analysis]] of patients at all levels of risk.<ref name="pmid16214597">{{cite journal |author=Baigent C, Keech A, Kearney PM, ''et al'' |title=Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins |journal=Lancet |volume=366 |issue=9493 |pages=1267-78 |year=2005 |pmid=16214597 |doi=10.1016/S0140-6736(05)67394-1}}</ref>


Studies of drugs other than statins show other drugs can lower the cholesterol, but without definite benefit on clinical events. Examples include [[randomized controlled trial]]s of [[fenofibrate]] (fenofibric acid) <ref name="pmid20228404">{{cite journal| author=ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al.| title=Effects of combination lipid therapy in type 2 diabetes mellitus. | journal=N Engl J Med | year= 2010 | volume= 362 | issue= 17 | pages= 1563-74 | pmid=20228404 | doi=10.1056/NEJMoa1001282 | pmc=PMC2879499 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20228404  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20922178 Review in: J Fam Pract. 2010 Oct;59(10):582-4]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20643983 Review in: Ann Intern Med. 2010 Jul 20;153(2):JC1-5] </ref>, [[ezetimibe]], [[torcetrapib]]<ref name="pmid17984165">{{cite journal| author=Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M et al.| title=Effects of torcetrapib in patients at high risk for coronary events. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 21 | pages= 2109-22 | pmid=17984165 | doi=10.1056/NEJMoa0706628 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17984165  }} </ref>, and [[niacin]].
Studies of drugs other than statins show other drugs can lower the cholesterol, but without definite benefit on clinical events. Examples include [[randomized controlled trial]]s of [[fenofibrate]] (fenofibric acid) <ref name="pmid20228404">{{cite journal| author=ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al.| title=Effects of combination lipid therapy in type 2 diabetes mellitus. | journal=N Engl J Med | year= 2010 | volume= 362 | issue= 17 | pages= 1563-74 | pmid=20228404 | doi=10.1056/NEJMoa1001282 | pmc=PMC2879499 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20228404  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20922178 Review in: J Fam Pract. 2010 Oct;59(10):582-4]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20643983 Review in: Ann Intern Med. 2010 Jul 20;153(2):JC1-5] </ref>, [[ezetimibe]], [[torcetrapib]]<ref name="pmid17984165">{{cite journal| author=Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M et al.| title=Effects of torcetrapib in patients at high risk for coronary events. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 21 | pages= 2109-22 | pmid=17984165 | doi=10.1056/NEJMoa0706628 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17984165  }} </ref>, and [[niacin]]<ref>{{cite web |url= http://www.nejm.org/doi/full/10.1056/NEJMoa1107579 |title=Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy |author=The AIM-HIGH Investigators |work=nejm.org |year=2011 [last update] |accessdate=November 16, 2011|doi=10.1056/NEJMoa1107579}}</ref>.


It is not clear whether to treat to LDL targets. Studies are currently evaluating this.<ref>[http://clinicaltrials.gov/ct2/show/NCT00202878 IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (Study P04103AM3)] Clinical Trials.gov</ref><ref>[http://clinicaltrials.gov/ct2/show/NCT01252875 Treat Stroke to Target (TST)] ClinicalTrials.gov <!-- search for cholesterol AND (target OR goal) AND (mortality OR death) AND random*--></ref>
It is not clear whether to treat to LDL targets. Studies are currently evaluating this.<ref>[http://clinicaltrials.gov/ct2/show/NCT00202878 IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (Study P04103AM3)] Clinical Trials.gov</ref><ref>[http://clinicaltrials.gov/ct2/show/NCT01252875 Treat Stroke to Target (TST)] ClinicalTrials.gov <!-- search for cholesterol AND (target OR goal) AND (mortality OR death) AND random*--></ref>

Revision as of 00:27, 16 November 2011

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Hypercholesterolemia&printable=yes
This editable Main Article is under development and subject to a disclaimer.

Hypercholesterolemia is "a condition with abnormally high levels of cholesterol in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population."[1] It should be differentiated from dyslipidemia, where the total cholesterol may not be abnormally high, but the ratios of lipid components are in an unhealthy reange.

Treatment

Antilipemic agents such as hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and clofibric acid derivatives can help.

A meta-analysis estimated that after 5 to 7 years of treatment with statins, the relative risk reduction of coronary heart disease events is decreased by approximately 30%[2][3]. More recently, a second meta-analysis reported an almost identical relative risk reduction of 29.2% in patients treated for 4.3 years [4]. A relative risk reduction of 19% in coronary mortality was found in a meta-analysis of patients at all levels of risk.[5]

Studies of drugs other than statins show other drugs can lower the cholesterol, but without definite benefit on clinical events. Examples include randomized controlled trials of fenofibrate (fenofibric acid) [6], ezetimibe, torcetrapib[7], and niacin[8].

It is not clear whether to treat to LDL targets. Studies are currently evaluating this.[9][10]

Clinical practice guidelines

Various clinical practice guidelines have addressed the treatment of hypercholesterolemia.

Clinical practice guidelines by the National Institute for Health and Clinical Excellence in 2008 recommend treatment if the estimated 10 year risk of cardiovascular disease is at least 20%.[11][12]

The American College of Physicians in 2004 addressed hypercholesterolemia in patients with diabetes [13]. Their recommendations are:

  • Recommendation 1: Lipid-lowering therapy should be used for secondary prevention of cardiovascular mortality and morbidity for all patients (both men and women) with known coronary artery disease and type 2 diabetes.
  • Recommendation 2: Statins should be used for primary prevention against macrovascular complications in patients (both men and women) with type 2 diabetes and other cardiovascular risk factors.
  • Recommendation 3: Once lipid-lowering therapy is initiated, patients with type 2 diabetes mellitus should be taking at least moderate doses of a statin (the accompanying evidence report states "simvastatin, 40 mg/d; pravastatin, 40 mg/d; lovastatin, 40 mg/d; atorvastatin, 20 mg/d; or an equivalent dose of another statin")[14].
  • Recommendation 4: For those patients with type 2 diabetes who are taking statins, routine monitoring of liver function tests or muscle enzymes is not recommended except in specific circumstances.

The National Cholesterol Education Program revised their 2001 guidelines[15] in 2004 to include goal LDL values.[16]; however, their 2004 revisions have been criticized for use of nonrandomized, observational data.[17] A decision analysis found that treating to targets is not efficient.[18]

Primary prevention

Two meta-analyses found that overall mortality is insignificantly reduced.[19][4]

However, two meta-analyses have reported that statins can significantly help in the primary prevention of coronary heart disease[5][20] However, one of these meta-analyses focused on patients at risk.[20] while the other did not stratify results based on underlying risk.[5]

An important randomized controlled trial included in the meta-analyses is the AFCAPS/TexCAPS.[21] The 10 year risk of coronary heart disease among an average patient in this study ((age 57, male, non-smoker, total and HDL cholesterol values of 221 mg/dL and 36 mg/dL, respectively, SBP 138 mm/Hg with medications for hypertension) was 12%.

Treating based on risk factors is probably better than treating to a specific target LDL cholesterol.[18] Using a calculator such as the NIH calculator:

For primary prevention in diabetes mellitus, the American College of Physicians states:[13][14]

  • Recommendation 2: Statins should be used for primary prevention against macrovascular complications in patients (both men and women) with type 2 diabetes and other cardiovascular risk factors.
  • Recommendation 3: Once lipid-lowering therapy is initiated, patients with type 2 diabetes mellitus should be taking at least moderate doses of a statin (the accompanying evidence report states "simvastatin, 40 mg/d; pravastatin, 40 mg/d; lovastatin, 40 mg/d; atorvastatin, 20 mg/d; or an equivalent dose of another statin")[14].

Treating patients with normal cholesterol level may benefit patients if their high sensitivity c-reactive protein is elevated according to the Jupiter randomized controlled trial.[22] However, in the Jupiter trial, only 16% of patients were taking aspirin.[22]

Combination treatment

It is not clear that combination therapy is better than high dose hydroxymethylglutaryl-coenzyme A reductase inhibitors.[23]

If treatment with a hydroxymethylglutaryl-coenzyme A reductase inhibitor does not achieve a desirable cholesterol, other drugs that have been studied include eicosapentaenoic acid which is a metabolite of fish oil.[24] Ezetimibe, a cholesterol-absorption inhibitor, was not clearly beneficial in a study of diabetes mellitus type 2[25] and a study of mixed primary prevention and secondary prevention[26]. Niacin has been studied with improvements in the LDL and HDL[27] with uncertain[28] effects on carotid intima-media thickness.

Secondary prevention

Clinical practice guidelines by the National Institute for Health and Clinical Excellence recommend a treatment goal of <4 mmol/l (154 mg/dl) for total cholesterol or a low density lipoprotein cholesterol concentration of <2 mmol/l (77 mg/dl).[11][12] A systematic review summarized randomized controlled trials in secondary prevention.[29]

Combination treatment

If treatment with a hydroxymethylglutaryl-coenzyme A reductase inhibitor does not achieve a desirable cholesterol, other drugs that may be added for additional benefit include niacin[30][31][28] and fish oil. Ezetimibe, a cholesterol-absorption inhibitor, was not clearly beneficial in a study of diabetes mellitus type 2[25] and a study of mixed primary prevention and secondary prevention[26].

Diabetic patients

For more information, see: Diabetes_mellitus_type_2#Hypercholesterolemia.


Whether diabetes is an equivalent risk factor to having an existing myocardial infarction is debated.[32]

Statin therapy prevents major vascular events in about 1 of every 24 patients with diabetes who use the treatment for 5 years if they are similar to the patients in the meta-analysis by Kearney et al (Number needed to treat is 24).[33]

Treating to a goal of LDL-C < 70 mg/dl and systolic blood pressure to < 115 mm Hg may cause regression of carotid intima-media thickness in a randomized controlled trial.[34]

Complementary and alternative medicine

Preliminary research suggests possible benefit from artichoke leaf.[35]

References

  1. ↑ Anonymous. Hypercholesterolemia. National Library of Medicine. Retrieved on 2008-01-18.
  2. ↑ Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN (2001). "Screening and treating adults for lipid disorders". American Journal of Preventive Medicine 20 (3 Suppl): 77–89. PMID 11306236. [e]
  3. ↑ Screening for Lipid Disorders: Recommendations and Rationale. Retrieved on 2007-10-17.
  4. ↑ 4.0 4.1 Thavendiranathan P, Bagai A, Brookhart M, Choudhry N (2006). "Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials". Arch Intern Med 166 (21): 2307-13. DOI:10.1001/archinte.166.21.2307. PMID 17130382. Research Blogging. Cite error: Invalid <ref> tag; name "pmid17130382" defined multiple times with different content
  5. ↑ 5.0 5.1 5.2 Baigent C, Keech A, Kearney PM, et al (2005). "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins". Lancet 366 (9493): 1267-78. DOI:10.1016/S0140-6736(05)67394-1. PMID 16214597. Research Blogging.
  6. ↑ ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al. (2010). "Effects of combination lipid therapy in type 2 diabetes mellitus.". N Engl J Med 362 (17): 1563-74. DOI:10.1056/NEJMoa1001282. PMID 20228404. PMC PMC2879499. Research Blogging. Review in: J Fam Pract. 2010 Oct;59(10):582-4 Review in: Ann Intern Med. 2010 Jul 20;153(2):JC1-5
  7. ↑ Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M et al. (2007). "Effects of torcetrapib in patients at high risk for coronary events.". N Engl J Med 357 (21): 2109-22. DOI:10.1056/NEJMoa0706628. PMID 17984165. Research Blogging.
  8. ↑ The AIM-HIGH Investigators (2011 [last update]). Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. nejm.org. Retrieved on November 16, 2011.
  9. ↑ IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (Study P04103AM3) Clinical Trials.gov
  10. ↑ Treat Stroke to Target (TST) ClinicalTrials.gov
  11. ↑ 11.0 11.1 Cooper A, O'Flynn N (2008). "Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance". BMJ. PMID 18511800. PMC 2405875. [e]
  12. ↑ 12.0 12.1 Anonymous (2008). Lipid modification. National Institute for Health and Clinical Excellence. Retrieved on 2008-08-26. Cite error: Invalid <ref> tag; name "urlNICE guidance by type" defined multiple times with different content
  13. ↑ 13.0 13.1 Snow V, Aronson M, Hornbake E, Mottur-Pilson C, Weiss K (2004). "Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians". Ann Intern Med 140 (8): 644-9. PMID 15096336. Cite error: Invalid <ref> tag; name "pmid15096336" defined multiple times with different content
  14. ↑ 14.0 14.1 14.2 Vijan S, Hayward RA (2004). "Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians". Ann. Intern. Med. 140 (8): 650-8. PMID 15096337. [e] Cite error: Invalid <ref> tag; name "pmid15096337" defined multiple times with different content Cite error: Invalid <ref> tag; name "pmid15096337" defined multiple times with different content
  15. ↑ Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).". JAMA 285 (19): 2486-97. PMID 11368702.
  16. ↑ Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ (2004). "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines". J. Am. Coll. Cardiol. 44 (3): 720-32. DOI:10.1016/j.jacc.2004.07.001. PMID 15358046. Research Blogging.
  17. ↑ Hayward RA, Hofer TP, Vijan S (2006). "Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem". Ann. Intern. Med. 145 (7): 520-30. PMID 17015870. [e]
  18. ↑ 18.0 18.1 Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S (2010). "Optimizing statin treatment for primary prevention of coronary artery disease.". Ann Intern Med 152 (2): 69-77. DOI:10.1059/0003-4819-152-2-201001190-00004. PMID 20083825. Research Blogging. Cite error: Invalid <ref> tag; name "pmid20083825" defined multiple times with different content
  19. ↑ Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I et al. (2010). "Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.". Arch Intern Med 170 (12): 1024-31. DOI:10.1001/archinternmed.2010.182. PMID 20585067. Research Blogging.
  20. ↑ 20.0 20.1 Brugts JJ, Yetgin T, Hoeks SE, et al. (2009). "The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials". BMJ 338: b2376. PMID 19567909. [e]
  21. ↑ Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. (1998). "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.". JAMA 279 (20): 1615-22. DOI:10.1001/jama.279.20.1615. PMID 9613910. Research Blogging.
  22. ↑ 22.0 22.1 Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ et al. (2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.". N Engl J Med 359 (21): 2195-207. DOI:10.1056/NEJMoa0807646. PMID 18997196. Research Blogging. Review in: Ann Intern Med. 2009 Jan 20;150(2):JC1-4 Review in: Evid Based Med. 2009 Apr;14(2):48
  23. ↑ Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M et al. (2009). "Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.". Ann Intern Med 151 (9): 622-30. DOI:10.1059/0003-4819-151-9-200911030-00144. PMID 19884623. Research Blogging.
  24. ↑ Yokoyama M, Origasa H, Matsuzaki M, et al (March 2007). "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis". Lancet 369 (9567): 1090–8. DOI:10.1016/S0140-6736(07)60527-3. PMID 17398308. Research Blogging.
  25. ↑ 25.0 25.1 Howard BV, Roman MJ, Devereux RB, et al (April 2008). "Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial". JAMA 299 (14): 1678–89. DOI:10.1001/jama.299.14.1678. PMID 18398080. Research Blogging.
  26. ↑ 26.0 26.1 Kastelein JJ, Akdim F, Stroes ES, et al (April 2008). "Simvastatin with or without ezetimibe in familial hypercholesterolemia". N. Engl. J. Med. 358 (14): 1431–43. DOI:10.1056/NEJMoa0800742. PMID 18376000. Research Blogging.
  27. ↑ McKenney JM, Jones PH, Bays HE, et al (June 2007). "Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)". Atherosclerosis 192 (2): 432–7. DOI:10.1016/j.atherosclerosis.2006.11.037. PMID 17239888. Research Blogging.
  28. ↑ 28.0 28.1 Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA (December 2004). "Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins". Circulation 110 (23): 3512–7. DOI:10.1161/01.CIR.0000148955.19792.8D. PMID 15537681. Research Blogging.
  29. ↑ Cholesterol Treatment Trialists’ (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C et al. (2010). "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.". Lancet 376 (9753): 1670-81. DOI:10.1016/S0140-6736(10)61350-5. PMID 21067804. Research Blogging.
  30. ↑ Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M et al. (2009). "Extended-release niacin or ezetimibe and carotid intima-media thickness.". N Engl J Med 361 (22): 2113-22. DOI:10.1056/NEJMoa0907569. PMID 19915217. Research Blogging.
  31. ↑ Brown BG, Zhao XQ, Chait A, et al. (November 2001). "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease". N. Engl. J. Med. 345 (22): 1583–92. PMID 11757504. [e]
  32. ↑ Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I (February 2009). "Is diabetes a coronary risk equivalent? Systematic review and meta-analysis". Diabet. Med. 26 (2): 142–8. DOI:10.1111/j.1464-5491.2008.02640.x. PMID 19236616. Research Blogging.
  33. ↑ Kearney PM, Blackwell L, Collins R, et al (2008). "Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis". Lancet 371 (9607): 117–25. DOI:10.1016/S0140-6736(08)60104-X. PMID 18191683. Research Blogging.
  34. ↑ Howard, B. V., Roman, M. J., Devereux, R. B., Fleg, J. L., Galloway, J. M., Henderson, J. A., et al. (2008). Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. JAMA, 299(14), 1678-1689. DOI:10.1001/jama.299.14.1678.
  35. ↑ Wider B, Pittler MH, Thompson-Coon J, Ernst E (2009). "Artichoke leaf extract for treating hypercholesterolaemia.". Cochrane Database Syst Rev (4): CD003335. DOI:10.1002/14651858.CD003335.pub2. PMID 19821306. Research Blogging.
Retrieved from "https://citizendium.org/wiki/index.php?title=Hypercholesterolemia&oldid=381966"